Influence of Low Molecular Weight Heparin on the Hemostatic System After Abdominal Surgery

Summary

The hemostatic effect of two low molecular weight heparin fractions and of one unfractionated heparin preparation administered subcutaneously b. i. d. was examined in 6 healthy subjects and in 53 patients after major abdominal surgery. Among other tests platelet count, prothrombin time, fibrinogen, β-thrombo- globulin, antithrombin, antiplasmin, FPA and F-CB 3 related antigen, as well as various heparin activities, were repeatedly determined pre- and postoperatively. Under all tested conditions the low molecular weight fractions induced higher heparin levels, both in terms of anti-Xa and of anti-thrombin activity. No further significant differences of the laboratory results between the treatment groups were documented. Total blood loss measured at the first postoperative day was higher in patients with malignancy and negatively correlated with antithrombin and antiplasmin levels, while no relation was observed with the heparin activities and the other tested parameters. Whereas evidence for a hemorrhagic property of the tested low molecular weight heparin fractions was found, a particular mechanism underlying this effect could not be identified.

Keywords

Thrombosis prophylaxis - Low molecular weight heparin - Postoperative hemostasis - Bleeding complications

• References

• 1 Barrowcliffe TW, Johnson EA, Eggleton CA, Kemball-Cook G, Thomas DP. Anticoagulant activities of high and low molecular weight heparin fractions. Br J Haematol 1979; 41: 573-583
• 2 Holmer E, Kurachi K, Söderström G. The molecular-weight dependence of the rate-enhancing effect of heparin on the inhibition of thrombin, factor Xa, factor IXa, factor XIa, factor XIIa and Kallikrein by antithrombin. Biochem J 1981; 193: 395-400
• 3 Schmitz-Huebner U, Balleisen L, Asbeck F, van de Loo J. In vivo studies on the inhibition of coagulation by fractionated heparin and by a heparin analogue. I. Effect of heparin fractions. Thromb Haemostas 1981; 46: 612-616
• 4 Schmitz-Huebner U, Lobreyer EM, van de Loo J. Nature of anti-Xa activity induced by a heparin analogue (SSHA) in vivo. Thromb Res 1982; 27: 757-762
• 5 Denton J, Lane DA, Thunberg L, Slater AM, Lindahl U. Binding of platelet factor 4 to heparin oligosaccharides. Biochem J 1983; 209: 455-460
• 6 Kakkar VV, Djazaeri B, Fok J, Scully M, Westwick J. Low molecular weight heparin and the prevention of postoperative deep vein thrombosis. In Heparin. New biochemical and medical aspects. Witt I. (Ed.) Walter de Gruyter; Berlin, New York: 1982. pp 175-202
• 7 Kakkar VV, Djazaeri B, Fok J, Scully MF, Westwick J. Low- molecular-weight heparin and prevention of postoperative deep vein thrombosis. Br Med J 1982; 284: 375-379
• 8 Carter CJ, Kelton JG, Hirsch J, Cerkus A, Santos AV, Gent M. The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits. Blood 1982; 59: 1239-1245
• 9 Schmitz-Huebner U, Bünte H, Freise G, Reers B, Rüschemeyer Ch, Scherer R, Schulte H, van de Loo J. Clinical efficacy of low molecular weight heparin in postoperative thrombosis prophylaxis. Klin Wochenschr 1984; 62: 349-353
• 10 Yin AN, Wessler S, Butler J. Plasma heparin: A unique practical, submicrogram sensitive assay. J Lab Clin Med 1973; 81: 298-310
• 11 Teien ET, Lie M, Abildgaard U. Assay of heparin in plasma using a chromogenic substrate. Thromb Res 1976; 8: 413-416
• 12 Blombäck M, Blombäck B, Olsson P, William-Olsson G, Senning A. Determination of heparin level of the blood. Acta Chir Scand 1959; 245 (suppl) 259-264
• 13 Ødegard OR. Evaluation of an amidolytic heparin cofactor assay method. Thromb Res 1975; 7: 351-360
• 14 Teger-Nilsson AC, Friberger P, Gyzander E. Determination of a new rapid plasmin inhibitor in human blood by means of a plasmin specific tripeptide substrate. Scand J Clin Lab Invest 1977; 37: 403-409
• 15 Gollwitzer R, Wood WG, Schramm W. Radioimmuntest für ein großes BrCN-Peptid der A-α-Kette des Fibrinogens zum Nachweis früher Fibrinolyseprodukte im Serum. In Fibrinolyse, Thrombose, Hämostase. Deutsch E, Lechner K. (Eds) Schattauer; Stuttgart - New York: 1980. pp 250-253
• 16 Sachs L. Angewandte Statistik. Springer; Berlin - Heidelberg - New York: 1978
• 17 Thomas DP, Merton RE. A low molecular weight heparin compared with unfractionated heparin. Thromb Res 1982; 28: 343-350
• 18 Nossel HC. Relative proteolysis of the fibrinogen Bβ chain by thrombin and plasmin as a determinant of thrombosis. Nature 1981; 291: 165-167
• 19 Bick RL. Alterations of hemostasis associated with malignancy: Etiology, pathophysiology and management. Semin Thromb Haemost 1978; 5: 1-26
• 20 Sun NC J, McAfee WM, Hum GJ, Weiner JM. Hemostatic abnormalities in malignancy, a prospective study of one hundred eight patients. Am J Clin Pathol 1979; 71: 10-16